Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of coadministration of RSVPreF3 OA vaccine with a COVID-19 mRNA vaccine in adults aged 50 years and older
NL-OMON59001Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of GSK3003899A and RH109 in respiratory syncytial virus disease (RSV) and coronavirus disease 2019 (COVID-19) (3 arms), sponsored by GSK. Primary endpoints: RSV-A neutralization titer group GMT ratio, RSV-B neutralization titer group GMT ratio and 1 more. Started Jun 2024; status: completed.
02
Drugs
GSK3003899ARH109
03
Conditions
respiratory syncytial virus disease (RSV)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON59001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59001.